- Cash and equivalents reached $456.2M as of Sept 30, 2026, extending funding runway into 2029.
- Q3 net loss increased to $46.4M ($3.19/share) vs. $21.7M YoY due to expanded R&D.
- Phase 1 healthy volunteer data for KRSA-028 expected mid-2027.
Why is $KRSA moving today? · SEC 8-K archive
$KRSA SEC Filing Alert & Real-Time AI Stock Impact Analysis
T0 SEO archive for $KRSA: filings appear instantly. AI score, direction and bullet analysis unlock publicly after 4 hours (VIP sees them live).
FAQ: $KRSA filing catalyst
Why did $KRSA trigger an AI stock catalyst alert?
$KRSA triggered a Stock Catalyst AI alert on 2026-11-05 00:00:00 UTC for a SEC 8-K filing (AI Score: +2.0/10). Headline: Korsana Biosciences Reports Q3 2026: $456.2M Cash Funds Runway into 2029. Key points: - Cash and equivalents reached $456.2M as of Sept 30, 2026, extending funding runway into 2029. - Q3 net loss increased to $46.4M ($3.19/share) vs. $21.7M YoY due to expanded R&D. - Phase 1 healthy volunteer data for KRSA-028 expected mid-2027.
How did $KRSA stock react after the SEC filing?
After the SEC 8-K for $KRSA, observed market reaction: T0 price $30.56. Past moves do not guarantee future results.
Where can I get real-time $KRSA SEC filing alerts?
Stock Catalyst AI pushes real-time SEC 8-K alerts for $KRSA via Telegram and the VIP Web Terminal from €10/month.